Monitor for future clinical trial results in Europe and any expansion of Australian reimbursement pathways, which could signal revenue inflection. The absence of serious adverse events in Australian patients is a positive safety signal but does not change the pre-revenue status. No financial data to trade on.
Price Chart
Executive Summary
Optimi Health Corp. announced completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, its highest-purity botanical psilocybin extract to date. The extract will support clinical research in Europe and reinforces commercial supply in Australia under the Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025. This is a manufacturing milestone for a pre-revenue-stage company with no financial data disclosed.
Key Facts
- Completed production run of naturally derived psilocybin extract with approximately 6% psilocybin content, highest-purity botanical extract to date.
- Extract earmarked for upcoming clinical research programs in Europe, supplying GMP-grade finished material into sponsor-led studies.
- Company's 5 mg psilocybin capsules are being prescribed for treatment-resistant depression in Australia under the TGA's Authorised Prescriber Scheme since September 2025.
- No serious adverse events reported among patients treated with psilocybin under the Australian Scheme as of December 2025.
- Company maintains a proprietary library of more than 200 distinct mushroom genetics.
Financial Impact
No financial figures disclosed; pre-revenue commercial-stage company with no revenue, earnings, or deal values reported.
Risk Factors
- Pre-revenue company with no disclosed financials; stock price driven by sentiment and pipeline milestones, not fundamentals.
- Forward-looking statements about clinical programs and supply initiatives are subject to regulatory and execution risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-237833 |
| Document: d35078d6k.htm | 0001193125-26-237833 |
| Document: 0001193125-26-237833-index-headers.html | 0001193125-26-237833 |
| Document: 0001193125-26-237833-index.html | 0001193125-26-237833 |
| Document: 0001193125-26-237833.txt | 0001193125-26-237833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 26, 2026 22w ago | 6-K | — | awaiting T+20 | — | — |
May 19, 2026 23w ago | F-1/A | $0.2352 | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | F-1/A | $0.2644 $0.2352 | ▼ −11.04% | ▼ −15.07% | — |
Apr 21, 2026 27w ago | F-1/A | $0.2680 $0.2352 | ▼ −12.24% | ▼ −15.40% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers